Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $7.40.

Several equities analysts have recently issued reports on the company. Guggenheim lifted their price target on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Zacks Research cut shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PYXS. Jacobs Levy Equity Management Inc. bought a new stake in Pyxis Oncology in the 3rd quarter worth about $134,000. Velan Capital Investment Management LP boosted its holdings in shares of Pyxis Oncology by 37.5% during the 3rd quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock valued at $122,000 after acquiring an additional 15,000 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter valued at about $749,000. Bank of America Corp DE grew its stake in shares of Pyxis Oncology by 2,690.9% in the third quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after acquiring an additional 593,853 shares during the period. Finally, Longaeva Partners L.P. purchased a new position in shares of Pyxis Oncology during the third quarter valued at approximately $1,117,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Stock Down 2.5%

Pyxis Oncology stock opened at $4.30 on Monday. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The company has a market capitalization of $267.72 million, a P/E ratio of -2.69 and a beta of 1.36. The stock’s 50 day moving average is $4.03 and its 200 day moving average is $2.33.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. As a group, equities analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.